CIDRAP newsletters options
Fall 2020 brought the biggest upheaval in public school enrollment in US history, with a 2.8% decline in public school enrollments.
Vaccine efficacy against ICU admission was 85% to 91% in adolescents amid the Omicron variant period.
The most common symptoms at 2 years were fatigue, memory loss, trouble concentrating, and insomnia.
COVID is at higher-than-expected levels in some parts of South America.
Influenza A currently makes up the majority of global detections, with H3N2 most common among subtyped samples.
Investigators say the dose of linezolid may have been too low and the duration of treatment too short.
The money will help CARB-X fund early-stage development of products to treat, prevent, and diagnose drug-resistant infections.
In November, Cameroon said it would receive 331,200 doses of the RTS,S vaccine, which is produced by GSK.
Mpox disease progression occurred in 5% of those who received Tpoxx early and in 27% of people who received it later or not at all.
Composite major cardiovascular events fell 27% in April 2020 and stayed below expected levels in March (−10%) and December (−20%).
COVID activity is high, but infections are causing less severe disease than earlier in the pandemic.
Interviews with national TB program managers indicate nearly 80% of patients with DR-TB will have access to shorter, all-oral regimens by 2026.
The most common symptoms were cough, fatigue, and memory loss.
The latest suspected cases stem from exposures at a daycare provider.
Though COVID wastewater and test positivity are higher than last year at this time, medical encounters are trending lower.
More attention must be paid to the mechanisms linking telehealth and healthcare use to avoid inadvertently deepening disparities, the authors said.
Clinicians were reminded of a 2021 TB outbreak, which involved 113 recipients in 18 states.
Scientists have identified a novel antibiotic class that inhibits one of the building blocks of the tough outer membrane of the highly drug-resistant pathogen.
Estimated effectiveness against intensive care unit admission was 73%.
The drug targets biofilm formation in bacteria that cause difficult-to-treat infections in CF patients.
